title: The therapeutic promise of the cancer stem cell concept.
abstract: Cancer stem cells (CSCs) are a subpopulation of tumor cells that selectively possess tumor initiation and self-renewal capacity and the ability to give rise to bulk populations of nontumorigenic cancer cell progeny through differentiation. As we discuss here, they have been prospectively identified in several human malignancies, and their relative abundance in clinical cancer specimens has been correlated with malignant disease progression in human patients. Furthermore, recent findings suggest that clinical cancer progression driven by CSCs may contribute to the failure of existing therapies to consistently eradicate malignant tumors. Therefore, CSC-directed therapeutic approaches might represent translationally relevant strategies to improve clinical cancer therapy, in particular for those malignancies that are currently refractory to conventional anticancer agents directed predominantly at tumor bulk populations.
authors.affiliation: Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, Massachusetts 02115, USA.
authors.forename: Natasha Y
authors.initials: NY
authors.lastname: Frank
authors.forename: Tobias
authors.initials: T
authors.lastname: Schatton
authors.forename: Markus H
authors.initials: MH
authors.lastname: Frank
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D002454:Cell Differentiation; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D014411:Neoplastic Stem Cells / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D009389:Neovascularization, Pathologic / Q000209:etiology; D015398:Signal Transduction / Q000187:drug effects; D019139:Tumor Escape; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A